Danaher Corporation $DHR Shares Acquired by Evelyn Partners Investment Management LLP

Evelyn Partners Investment Management LLP grew its position in shares of Danaher Corporation (NYSE:DHR) by 1,105.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,751 shares of the conglomerate’s stock after purchasing an additional 83,224 shares during the quarter. Danaher makes up about 0.8% of Evelyn Partners Investment Management LLP’s portfolio, making the stock its 29th biggest holding. Evelyn Partners Investment Management LLP’s holdings in Danaher were worth $17,927,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. Evelyn Partners Investment Management Europe Ltd raised its position in shares of Danaher by 217.0% in the second quarter. Evelyn Partners Investment Management Europe Ltd now owns 3,192 shares of the conglomerate’s stock worth $630,000 after acquiring an additional 2,185 shares during the period. Journey Strategic Wealth LLC increased its stake in shares of Danaher by 44.3% in the 2nd quarter. Journey Strategic Wealth LLC now owns 6,059 shares of the conglomerate’s stock valued at $1,197,000 after purchasing an additional 1,860 shares in the last quarter. Georgetown University raised its holdings in Danaher by 30.1% in the 2nd quarter. Georgetown University now owns 48,069 shares of the conglomerate’s stock worth $9,496,000 after purchasing an additional 11,135 shares during the period. Franklin Resources Inc. boosted its position in Danaher by 4.0% during the second quarter. Franklin Resources Inc. now owns 4,822,442 shares of the conglomerate’s stock worth $952,625,000 after purchasing an additional 186,357 shares in the last quarter. Finally, White Pine Capital LLC grew its holdings in Danaher by 1.4% in the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after purchasing an additional 49 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 2.3%

Shares of Danaher stock opened at $227.34 on Friday. The company has a fifty day simple moving average of $208.58 and a 200-day simple moving average of $201.97. The stock has a market cap of $160.58 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.71 EPS. On average, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is presently 26.39%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their target price on Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Robert W. Baird set a $247.00 target price on shares of Danaher in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Barclays upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $243.39.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 in the last 90 days. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.